---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-016847"
form_type: "8-K"
ticker: "CHRS"
cik: "0001512762"
company_name: "Coherus Oncology, Inc."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T03:29:31.662584+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Coherus Q3 net loss widens to $86.7M on 45% revenue decline; CIMERLI projected >$100M in 2023

## Summary
- Q3 2022 net revenue $45.4M (down from $82.5M YoY); net loss $86.7M ($1.11 loss per share).
- GAAP EPS loss $1.11 vs $0.49 loss YoY; non-GAAP EPS loss $0.96 vs $0.34 loss.
- CIMERLI launched Oct 3, 2022; 2023 net sales projected >$100M; leading biosimilar market share.
- Toripalimab BLA target action date Dec 23, 2022; FDA inspections hindered by COVID travel restrictions.
- Targeting profitability in 2024; planning 2023 launches of YUSIMRY, toripalimab, UDENYCA OBI.

## SEC filing metadata
- accession: 0001558370-22-016847
- form_type: 8-K
- ticker: CHRS
- cik: 0001512762
- company_name: Coherus Oncology, Inc.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1512762/000155837022016847/0001558370-22-016847-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1512762/000155837022016847/chrs-20221108x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-016847
- JSON: https://secwatch.observer/filing/0001558370-22-016847.json
- Plain text: https://secwatch.observer/filing/0001558370-22-016847.txt

## Key facts
- Earnings Releases
  Coherus Oncology, Inc. reported third quarter ended September 30, 2022 results: revenue $45.4 million, net income Net loss of $86.7 million, or $(1.11) per share, EPS $(1.11) per share.
  - Period: third quarter ended September 30, 2022
  - Revenue: $45.4 million
  - Net income: Net loss of $86.7 million, or $(1.11) per share
  - EPS: $(1.11) per share
  - Result: reported results
  source text: Net revenue, consisting primarily of net sales of UDENYCA®, was $45.4 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1512762/000155837022016847/0001558370-22-016847-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.